Abstract:Background To our knowledge, no randomised study has compared postmastectomy hypofractionated radiotherapy with conventional fractionated radiotherapy in patients with breast cancer. This study aimed to determine whether a 3-week schedule of postmastectomy hypofractionated radiotherapy is as efficacious and safe as a 5-week schedule of conventional fractionated radiotherapy. Methods This randomised, non-inferiority, open-label, phase 3 study was done in a single academic hospital in China. Patients aged 18-75 years who had undergone mastectomy and had at least four positive axillary lymph nodes or primary tumour stage T3-4 disease were eligible to participate. Patients were randomly assigned (1: 1) according to a computer-generated central randomisation schedule, without stratification, to receive chest wall and nodal irradiation at a dose of 50 Gy in 25 fractions over 5 weeks (conventional fractionated radiotherapy) or 43.5 Gy in 15 fractions over 3 weeks (hypofractionated radiotherapy). The modified intention-to-treat population (including all eligible patients who underwent randomisation but excluding those who were considered ineligible or withdrew consent after randomisation) was used in primary and safety analyses. The primary endpoint was 5-year locoregional recurrence, and a 5% margin was used to establish non-inferiority (equivalent to a hazard ratio <1.883). This trial is registered at ClinicalTrials.gov, number NCT00793962. Findings Between June 12, 2008, and June 16, 2016, 820 patients were enrolled and randomly assigned to the conventional fractionated radiotherapy group (n=414) or hypofractionated radiotherapy group (n=406). 409 participants in the conventional fractionated radiotherapy group and 401 participants in the hypofractionated radiotherapy group were included in the modified intention-to-treat analyses. At a median follow-up of 58.5 months (IQR 39.2-81.8), 60 (7%) patients had developed locoregional recurrence (31 patients in the hypofractionated radiotherapy group and 29 in the conventional fractionated radiotherapy group); the 5-year cumulative incidence of locoregional recurrence was 8.3% (90% CI 5.8-10.7) in the hypofractionated radiotherapy group and 8.1% (90% CI 5.4-10.6) in the conventional fractionated radiotherapy group (absolute difference 0.2%, 90% CI -3.0 to 2.6; hazard ratio 1.10, 90% CI 0.72 to 1.69; p< 0.0001 for non-inferiority). There were no significant differences between the groups in acute and late toxicities, except that fewer patients in the hypofractionated radiotherapy group had grade 3 acute skin toxicity than in the conventional fractionated radiotherapy group (14 [3%] of 401 patients vs 32 [8%] of 409 patients; p< 0.0001). Interpretation Postmastectomy hypofractionated radiotherapy was non-inferior to and had similar toxicities to conventional fractionated radiotherapy in patients with high-risk breast cancer. Hypofractionated radiotherapy could provide more convenient treatment and allow providers to treat more patients. Copyright (c) 2019 Elsevier Ltd. All rights reserved.

Postmastectomy Hypofractionation Radiotherapy in High-Risk Breast Cancer Patients: A Phase Ⅰ/Ⅱ Clinical Trial

Hypofractionated Versus Conventional Fractionated Postmastectomy Radiotherapy for Patients with High-Risk Breast Cancer: a Randomised, Non-Inferiority, Open-Label, Phase 3 Trial

Hypofractionated Radiation Therapy after Mastectomy for the Treatment of High-Risk Breast Cancer: 5-Year Follow-Up Result of a Randomized Trial

Clinical trial of hypofractionation radiotherapy for early stage breast cancer after breast conserving surgery

Phase Ⅱ Clinical Trial of Central Hypofractionated Three-Dimensional Radiotherapy for Patients with Early-Stage Breast Cancer after Breast-Conserving Surgery

Acute Toxicity Effect of Hypofractionated Whole-Breast Radiation Therapy with Simultaneous Boost of the Tumor Bed in Patients with Breast-Conserving Treatment

Clinical Observation of Postoperative Hypofractionated Radiotherapy to Chest Wall in Breast Cancer

Comparing hypofractionated to conventional fractionated radiotherapy in postmastectomy breast cancer: a meta-analysis and systematic review

Long-term treatment results of conventional and hypofractionation radiotherapy in postmastectomy cancer breast patients: A retrospective study from rural cancer center of Maharashtra, India

The Role of Postmastectomy Radiation Therapy in Locally Advanced Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Mastectomy

Hypofractionated versus Conventional Postmastectomy Irradiation for Breast Cancer: Comparison of Acute Skin Toxicity

Outcome of Postmastectomy Radiotherapy after Primary Systemic Treatment in Patients with Clinical T1-2N1 Breast Cancer.

Hypofractionated Stereotactic Radiation Therapy for Advanced Non-Small Cell Lung Cancer: Report on Clinical Outcome and Toxicity

Delay in Initiating Postmastectomy Radiotherapy is Associated with Inferiorsurvival Outcomes for Locally Advanced Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Mastectomy

Accelerated Hypofractionated Whole-Breast Irradiation with Concomitant Daily Boost Using Intensity-Modulated Radiation Therapy in Early Breast Cancer

Similar Outcomes of Standard Radiotherapy and Hypofractionated Radiotherapy Following Breast-Conserving Surgery.

Breast cancer hypofractionated radiotherapy in 2-weeks with 2D technique: 5-year clinical outcomes of a phase 2 trial

Impact of Postmastectomy Radiotherapy on Locoregional Control and Disease-Free Survival in Patients with Breast Cancer Treated with Neoadjuvant Chemotherapy.

Prospective Phase Ⅱ Trial of Hypofractionated Intensity-Modulated Radiotherapy for Localized Prostate Cancer

Abstract P1-14-18: Postmastectomy Radiotherapy Improves the Outcomes of Stage III Breast Cancer Patients with Negative Lymph Nodes after Neoadjuvant Chemotherapy

Ott_a_289937 773..783